Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer – Medical Xpress
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic cast…
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
Noosa News18 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News20 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
Noosa News16 hours agoFranz Ferdinand: Australian Tour 2025
-
General17 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win